NovaBay Pharmaceuticals Reports Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
NovaBay Pharmaceuticals Reports Third Quarter 2014 Financial Results and a Clinical/Business Update

Q3 Commercial Highlights:

  • Initiation of the marketing campaign and commercialization effort for NovaBay's new product, i-Lid™ Cleanser, with medical sales representatives deployed in 10 major metropolitan areas across the United States.
  • Creation of an Optometry Advisory Board and expansion of Ophthalmology Advisory Board to help oversee the development and marketing of NovaBay's i-Lid Cleanser .
  • Clearance of NovaBay's NeutroPhase ® Skin and Wound Cleanser by China's Food and Drug Administration with upcoming product launch in mainland China by partner, China Pioneer Pharma.

EMERYVILLE, Calif., Nov. 12, 2014 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, today reported third quarter 2014 financial results and provided an update on its clinical and commercialization progress.

"Our newly launched sales and marketing campaign for i-Lid Cleanser initially targets major urban areas where large numbers of individuals suffer from dry-eye and blepharitis. These markets include New York City, Los Angeles, Boston, Atlanta, San Francisco and other high value markets around the United Sates," commented Ron Najafi, Ph.D., Chairman and CEO of NovaBay Pharmaceuticals.

"Once eye care professionals prescribe i-Lid Cleanser and see positive results, we believe they will realize that it offers a marked improvement in the standard of care for patients with common conditions like dry eye syndrome associated with blepharitis and meibomitis," added Dr. Najafi.

Third Quarter 2014 Results

Net loss for the quarter ended September 30, 2014 was $4.2 million, compared to a net loss of $3.8 million for the same period last year. The higher net loss was mainly due to the fact that we recorded collaboration revenue from Galderma in 2013 and did not in 2014.

Cash, cash equivalents, and short-term investments decreased by approximately $4.0 million to $9.1 million on September 30, 2014, compared with $13.1 million on December 31, 2013. The decrease in cash balance was primarily attributable to our spending in multiple clinical trials, partially offset by $6.0 million in net cash proceeds from a March 2014 equity financing.

NovaBay's license, collaboration, distribution and product revenue for the quarter ended September 30, 2014 was $0.2 million, compared to $1.1 million for the same period last year. The decrease in license, collaboration, distribution and product revenue was related to the full amortization of the upfront payments from Galderma in 2013 and the end of the FTE funding from the same contract.

Research and development expenses for the three months ended September 30, 2014, were $2.3 million, compared to $2.5 million for the same period last year. The changes over the period relate to the decrease in clinical activities as NovaBay completed its adenoviral conjunctivitis trial in March 2014 and its urology (UCBE) trial in the second half of 2013.

Sales, general and administrative expenses for the three months ended September 30, 2014 were $1.9 million, compared to $1.5 million for the same period last year. The increase was due to $0.5 million related to sales and marketing activities for i-Lid Cleanser in the three months ended September 30, 2014. The increase was partially offset by lower travel and entertainment expenses in 2014.

Q3 and Recent Business and Clinical Updates

  • October: Announced that NovaBay's i-Lid Cleanser with Neutrox was added to the Vision Source Independent Optometry Network, the largest independent optometry network in the country.
  • September: Announced that China's Food and Drug Administration had cleared NovaBay's  NeutroPhase Skin and Wound Cleanser for sale throughout mainland China. We will be shipping NeutroPhase to China to support launch of the product by China Pioneer Pharma, which placed its first order in October, in preparation of launch of NeutroPhase Skin and Wound Cleanser in China.
  • September: Announced creation of an Optometry Advisory Board to help oversee the development and marketing of NovaBay's  i-Lid Cleanser  and other eye lid hygiene products. The five members of the new board are nationally known eye care professionals.
  • September:  Featured i-Lid Cleanser  with Neutrox™ for the first time at the International Vision Expo & Conference, one of the most important contact lens and eye product conferences, covering everything from the latest medical information to trends in eyewear fashion.
  • August: Initiated a marketing campaign and commercialization effort for the company's new product, i-Lid Cleanser, led by Glenn Moro, NovaBay's new Vice President of Sales and Marketing. NovaBay's i-Lid Cleanser  sales force has been deployed in 10 major metropolitan areas across the United States.
  • August: Announced that NovaBay's NVC-422 ophthalmic formulation did not meet the primary or secondary endpoints in its Phase 2 BAYnovation clinical study in patients with adenoviral conjunctivitis. NovaBay does not intend to initiate any new studies of NVC-422 for this indication.

Forward-Looking Statements

This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs.   These statements include, but are not limited to, statements regarding regulatory approvals for our products, the anticipated market acceptance of our products, and the company's expected future financial results. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements.   Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in development, clinical trial, regulatory approval, production and marketing of the company's product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs.   Other risks relating to NovaBay and Aganocide compounds, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading " Risk Factors ."  The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Stay informed on NovaBay's progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay's Website
 
For Investment Inquiries:
Thomas J. Paulson
Chief Financial Officer
510-899-8809
Contact Tom
 
For NovaBay i-Lid Cleanser purchasing information, please contact:
Toll-Free: 1-800-890-0329
Contact i-Lid Cleanser
www.ilidcleanser.com
 
NOVABAY PHARMACEUTICALS, INC.
CONSOLIDATED BALANCE SHEETS
 
  September 30, December 31,
  2014 2013
(in thousands, except per share data) (unaudited)  
ASSETS    
Current assets:    
Cash and cash equivalents  $ 7,884  $ 10,500
Short-term investments   1,251  2,553
Accounts receivable  364  784
Inventory  405  231
Prepaid expenses and other current assets  514  723
Total current assets  10,418  14,791
Property and equipment, net   478  718
Other assets  147  141
TOTAL ASSETS  $ 11,043  $ 15,650
     
LIABILITIES AND STOCKHOLDERS' EQUITY    
Liabilities:    
Current liabilities:    
Accounts payable  $ 918  $ 1,674
Accrued liabilities   1,176  1,616
Deferred revenue  259  337
Total current liabilities  2,353  3,627
Deferred revenues - non-current  2,212  1,534
Deferred rent  164  136
Warrant liability  624  1,837
Total liabilities  5,353  7,134
     
Stockholders' equity:    
Preferred stock, $0.01 par value; 5,000 shares authorized; none outstanding at September 30, 2014 and December 31, 2013  —   — 
Common stock, $0.01 par value; 120,000 shares authorized at September 30, 2014 and 65,000 shares authorized at December 31, 2013; 51,143 and 44,624 issued and outstanding at September 30, 2014 and December 31, 2013, respectively  511  446
     
Additional paid-in capital  72,267  64,438
Accumulated other comprehensive loss  (9)  (15)
Accumulated deficit during development stage  (67,079)  (56,353)
Total stockholders' equity  5,690  8,516
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY  $ 11,043  $ 15,650
     
NOVABAY PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
 
  Three Months Ended
September 30,
Nine Months Ended
September 30,
 
(in thousands, except per share data) 2014 2013 2014 2013 Cumulative Period
from July 1, 2002
(inception) to
September 30,
2014
Sales:          
Product revenue  $ 90  $ (1)  $ 299  $ 78  $ 536
Cost of goods sold  42  43  189  82  359
Gross profit  48  (44)  110  (4)  177
           
Other revenue:          
License, collaboration and distribution revenue  23  1,035  99  2,739  60,598
Other revenues  39  65  165  150  478
Total other revenue  62  1,100  264  2,889  61,076
           
Operating expenses:          
Research and development  2,312  2,513  7,078  8,424  79,685
Sales, general and administrative  1,911  1,525  5,273  5,081  51,240
Total operating expenses  4,223  4,038  12,351  13,505  130,925
Operating loss  (4,113)  (2,982)  (11,977)  (10,620)  (69,672)
           
Non-cash gain (loss) on changes in fair value of warrants  (104)  (866)  1,213  (1,282)  1,365
Other income (expense), net  (2)  3  48  8  1,315
           
Loss before provision for income taxes  (4,219)  (3,845)  (10,716)  (11,894)  (66,992)
Provision for income taxes  —   (3)  (10)  (11)  (87)
Net loss  (4,219)  (3,848)  (10,726)  (11,905)  (67,079)
           
Change in unrealized gains (losses) on available-for-sale securities  3  6  6  (13)  (11)
Comprehensive loss  $ (4,216)  $ (3,842)  $ (10,720)  $ (11,918)  $ (67,090)
           
Net loss per share:          
Basic and diluted  $ (0.08)  $ (0.10)  $ (0.22)  $ (0.32)  
Shares used in per share calculations:          
Basic and diluted  50,821  37,467  48,995  37,166  
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 101

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
Linkind's Best Buy Push Tests Smart Outdoor Demand

Updated Category News Views 160

Holiday lights have quietly become a year-round hardware category, and Linkind wants a louder seat at the table. The smart-lighting brand says three outdoor products have been in Best Buy stores across the United States since October 17, 2026: permanent exterior lights, decorative string lights, and solar pathway lights. That is a real distribution step, not some grand...

Continue Reading
Blue Diamond's $1 Billion Brand Meets Farm Realities

Updated Category News Views 56

A Ten-Cent Signal Carries Real Weight A ten-cent edge over the industry benchmark may not excite the cocktail-party crowd, but almond growers notice every penny when fertilizer, power and pest control keep gnawing at the farm gate. Blue Diamond Growers says it delivered payments roughly 10 cents above the benchmark in its latest year, alongside net profit that came in...

Continue Reading
Kendra Scott’s Dolly Tribute Tests Purposeful Luxury

Updated Category News Views 87

Butterflies, music notes, and a $70 pendant are carrying a surprisingly serious brand message this November. Kendra Scott’s new Dolly Parton Tribute Collection is plainly built to celebrate Dolly’s style, but it also shows how a consumer brand can make sentiment do some commercial heavy lifting without turning the whole thing into mush. The collection arrived November...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Vector Adds Mesa Division 10 Veteran for Arizona Growth

Updated Category News Views 61

A toilet-partition deal rarely raises eyebrows, but this one has the sturdy logic investors ought to notice. Vector Building Products has acquired Mesa-based Partitions & Accessories Co., a Division 10 specialist that has served Arizona contractors since 1978. It is not glamorous work. It is, however, the sort of necessary, specification-driven business that gets embedded...

Continue Reading
Chemours Legal Succession Gets a Long Transition Runway

Updated Category News Views 0

A corporate-law handoff rarely sets pulses racing, but this one deserves a proper look. Chemours is replacing its long-serving general counsel while keeping the departing executive in the building for four additional months. That is not flashy, and thank goodness for that. In a global chemicals company, legal leadership touches regulation, compliance, governance,...

Continue Reading
Villa Group’s Punta Mita Bet Adds 305 Luxury Resort Keys

Updated Category News Views 102

A 12.6-acre slice of Riviera Nayarit coastline is about to get a very expensive makeover, assuming The Villa Group can turn a handsome plan into a functioning resort without the usual development headaches. The company says it has acquired a beachfront parcel in Litibú and intends to build Villa La Valencia Punta Mita, a 305-accommodation luxury property aimed squarely...

Continue Reading
Premier Energy's €850M Debt Bet on Evryo Nears Close

Updated Category News Views 27

A Bridge Loan Gives Way to a Real Commitment Eight hundred and fifty million euros is not the sort of number a company tosses around for decoration. Premier Energy has secured a five-year senior facilities agreement to fund its planned acquisition of Evryo Group, including electricity distribution subsidiary Distribu?ie Energie Oltenia S.A., and to refinance roughly...

Continue Reading
Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 106

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading

Top 5 Most Recently Viewed Articles

Latin Metals Gears Up for Drilling at Organullo Gold Project

Updated Category News Views 176

Latin Metals Achieves Drilling Milestone for Organullo Gold Project Latin Metals Inc. (TSXV: LMS) is excited to announce that it has successfully secured a crucial permit for exploration drilling at the Organullo Gold Project. This approval is a significant step forward in their commitment to mineral exploration in Argentina. What the Drill Permit Means for Latin Metals...

Continue Reading
TheSushiDragon Partners with StreamerDap to Empower Creators

Updated Category News Views 444

TheSushiDragon Joins StreamerDap as Co-Owner In a groundbreaking move for the live streaming community, TheSushiDragon, a prominent Twitch creator, has officially entered an equity partnership with StreamerDap, a leading platform revolutionizing the sponsorship landscape for creators. This innovative partnership aims to enhance the creator experience, making sponsorships...

Continue Reading
Tariffs, Inflation Insights: What Lies Ahead for Markets

Updated Category News Views 198

Market Trends: Understanding Recent Developments The market landscape has shown itself to be quite dynamic recently. As US President Donald Trump indicates the possibility of increased tariffs, there remains a juxtaposition of hope and uncertainty in the air. While discussions of a potential peace agreement between Russia and Ukraine seem to be gaining momentum, this has...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Bloom Energy Partners with Oracle to Boost AI Infrastructure

Updated Category News Views 301

Bloom Energy and Oracle: A Strategic Collaboration Bloom Energy Corp (NYSE: BE) is experiencing a notable surge in its stock prices following a recent announcement that highlights a significant partnership with Oracle Corp (NYSE: ORCL). This new collaboration aims to utilize Bloom's innovative fuel cell technology to deliver onsite power solutions for selected Oracle...

Continue Reading